Business
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for I...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis \n\n\n\n\n Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024\n \n\n 50% Growth in Revenue for International Medical Cannabis\n \n\n International Medical sales now 57% of Total Revenue\n \n\n Cash Balance of $10.4 Million at the end of Q2, Increased from $8.4 Million in Q1 2025\n \n\n Management to Host Conference Call / Webcast on August 14\n \n th\n \n , 2025 at 10:00 am ET\n \n\n\n\n\n TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) --\n \n MediPharm Labs Corp.\n \n (TSX:\n \n\n\n LABS\n \n\n\n ) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\" or the \"Company\"), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2025.\n \n\n MediPharm achieved strong year-over-year revenue growth in Q2 2025 and continued to advance its international medical cannabis strategy, supported by a solid balance sheet and strategic cost management. During the quarter, MediPharm successfully defended a proxy contest, with shareholders voting three-to-one in support of the Company’s board of directors and strategic direction. The Company saw record shareholder engagement, demonstrating strong alignment with management’s proven strategy for creating long-term value.\n \n\n\n “We are pleased with our strong year-over-year revenue growth and continued momentum in international markets,” said David Pidduck, CEO of MediPharm Labs. “While the second quarter included the cost and distraction of a proxy contest, our team remained focused and delivered solid results. I want to thank our shareholders again for their continued support and engagement. We are aligned in our vision to build a profitable, cash flow-positive business, and remain confident in our path forward.”\n \n\n Greg Hunter, CFO of MediPharm Labs, added, “The second quarter demonstrated the resilience of our commercial strategy, with 14 percent year-over-year revenue growth to $11.8M, and an increased cash balance at the end of Q2, despite the financial impact of the proxy contest. As we move forward, management remains focused on and relentless in driving further revenue growth and contin...